PTC Therapeutics - Biotech Company Impresses with Strong Pipeline!
Reading Time: 1 minute
Business Driver: PTC Therapeutics specializes in the development of therapies and medications for the treatment of rare diseases. The company focuses on innovative approaches such as RNA splicing modulation and gene therapy to address diseases that are currently difficult to treat. PTC Therapeutics already has several approved medications and therapies, including "Evrysdi" (risdiplam) for the treatment of Spinal Muscular Atrophy, "Translarna" (ataluren) and "Emflaza" (deflazacort) for Duchenne Muscular Dystrophy, as well as the gene therapy "Upstaza/Kebilidi"...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
